Ignite Proteomics, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), collaborates with Inova Health for a biomarker study in late-stage cancers.
The collaboration involves using Ignite's Reverse Phase Protein Array (RPPA) technology on tumor samples from patients with gastrointestinal cancers.
Up to 600 tumor samples will be analyzed to provide actionable biomarker data for therapy decisions in collaboration with Inova's Molecular Tumor Board.
Precision Oncology Trial
First trial using Functional Proteomics for treatment decisions in late-stage cancers.
Actionable Biomarker Data
Analysis of tumor samples to guide therapy responses in gastrointestinal cancers.
Significant Research Collaboration
One of the most substantial research collaborations for Ignite Proteomics contributing to 2025 revenue.
- The collaboration aims to accelerate precision medicine approaches for gastrointestinal cancer patients.
- It provides a novel approach by directly measuring protein drug targets for effective therapy decisions in late-stage cancers.
The collaboration between Ignite Proteomics and Inova Health signifies the commitment to advancing precision oncology and personalized treatment for patients with late-stage cancers. This partnership opens new possibilities for therapy guidance based on protein biomarker data.